# Avenzo Therapeutics

Source: https://onco.cc/companies/avenzo/  
OnCo record `avenzo` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Avenzo in-licenses Chinese assets, including the Nectin-4×TROP2 bispecific ADC AVZO-103 and a CDK2 inhibitor.

## Summary

Avenzo Therapeutics, based in San Diego, in-licenses Chinese oncology assets for Western development, including the Nectin-4 by TROP2 bispecific antibody-drug conjugate AVZO-103 and a CDK2 inhibitor. Its pipeline comprises AVZO-103, AVZO-021, the CDK2 inhibitor, and AVZO-1418, an EGFR by HER3 ADC. OnCo links it to Nectin-4 and TROP2 as targets and to the bispecific ADC technology. Whether a company that licenses rather than discovers can differentiate in a crowded bispecific ADC field is the open question. The bispecific ADC page carries the wider context.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: San Diego, CA
- Type: biotech
- Website: https://www.avenzotx.com

## Sources

- Official website: https://www.avenzotx.com

## Connected records

- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- targets: [Nectin-4](https://onco.cc/targets/nectin4/), [TROP2](https://onco.cc/targets/trop2/)
- drugs: [AVZO-021](https://onco.cc/drugs/avzo-021/), [AVZO-023](https://onco.cc/drugs/avzo-023/)
- trials: [AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)](https://onco.cc/trials/nct07038343/), [BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)](https://onco.cc/trials/nct07193511/), [ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors](https://onco.cc/trials/nct06998407/), [Study of AVZO-021 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct05867251/)
- technologies: [Bispecific ADC](https://onco.cc/technologies/bispecific-adc/)
- companies: [SR One](https://onco.cc/companies/sr-one/)

---
JSON: https://onco.cc/api/v1/entities/avenzo.json